By Sabela Ojea

AstraZeneca PLC (AZN.LN) said Friday that a supplemental biologics license application and granted priority review for the Imfinzi drug, which fights against untreated extensive-stage small-cell lung cancer, has been accepted by the U.S. Food and Drug Administration.

The drug maker said a prescription-drug user fee act date--the deadline for the FDA to review the application--is set for the first quarter of 2020.

Small-cell lung cancer is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly, the London-listed company said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 29, 2019 02:28 ET (07:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.